In animal studies, ketamine and psilocybin open a short window when the brain forms new connections more easily. Ayahuasca and ibogaine may do the same. That shared window is why people compare them for depression. They differ in how they act, how long a session lasts, what can go wrong and how far each has got toward being a prescribed medicine. Ketamine is already prescribed: one molecule, a measurable dose, randomised trials behind it. Ayahuasca is a brew with no fixed dose, and that is a large part of why it stays outside medicine.
How ketamine, psilocybin, ayahuasca and ibogaine compare
Ketamine is a prescribed medicine with randomised trials in depression. Psilocybin is in clinical trials as a synthetic formulation. Ayahuasca and ibogaine are plant preparations studied mostly in early or uncontrolled work. Here they are compared on the points people ask about first.
| Ketamine | Psilocybin | Ayahuasca | Ibogaine | |
|---|---|---|---|---|
| Acts on | NMDA receptors, the glutamate system | Serotonin 5-HT2A receptors | DMT on serotonin receptors, made active by chemicals from the vine | Many targets at once, including NMDA and opioid receptors |
| What it is | A synthetic drug | In trials, a synthetic formulation | A brew of plants, different from batch to batch | An alkaloid (the plant’s active chemical) from the iboga plant, no standard formulation |
| Status | Licensed anaesthetic, prescribed off-label for depression; esketamine nasal spray is licensed for treatment-resistant depression | Schedule I in the US; legal at licensed centres in Oregon and Colorado | DMT is Schedule I in the US | Schedule I in the US; no regulatory framework in several countries |
| Where it happens | Clinics, on a doctor’s prescription | Licensed centres in Oregon and Colorado, and clinical trials | Ceremonies outside medical regulation | Clinics in countries that do not restrict it, such as Mexico |
| Session | A 40-minute infusion | A session day of about eight hours with two facilitators | Effects peak 1.5 to 2 hours after drinking | Acute phase of about 4 to 8 hours, heart monitored for 12 to 16 hours |
| Evidence in depression | 64% response at 24 hours against 28% on an active placebo | 25 mg beat a 1 mg control dose at three weeks | Registered trials are mostly early phase | No randomised trials; early open studies, such as one of 30 veterans |
| Main risk | Dizziness, dissociation, a brief rise in blood pressure | Headache, nausea, dizziness; suicidal thoughts reported in trials | Dangerous interactions with some depression medication | Fatal heart rhythm problems on record |
In the table, off-label means prescribed for a use outside the drug’s original licence, Schedule I is the US category for drugs with no accepted medical use, and an active placebo is a drug with noticeable effects of its own.
Is ketamine a psychedelic? Different doors into the brain
Yes, in the broad sense. Ketamine changes perception and can bring a strong sense of detachment from the body, which is called dissociation. It gets there through a different door from psilocybin and ayahuasca. Dr Nataliya Vorobyeva, a neuroscientist who founded Hive Bio, put it this way in a conversation on The Integration Room:
“Ketamine is a synthetic psychedelic. Its main benefit is that it catalyses neuroplasticity for quite a long time.”
How long that period lasts in people, and how it compares between substances, has not been measured head to head.
Ketamine blocks NMDA receptors, part of the brain’s glutamate system. In a 2010 study in rats published in Science, Li and colleagues found that this switched on a signalling pathway called mTOR and built new synapses in the prefrontal cortex within 24 hours. Blocking mTOR removed the effect.
Psilocybin acts on serotonin 5-HT2A receptors. Carhart-Harris and Nutt (Journal of Psychopharmacology, 2017) link that receptor to the brain’s capacity for change, a different serotonin pathway from the one SSRI antidepressants mainly work through. The DMT in ayahuasca also acts on serotonin receptors, and a 2012 study by Riba and colleagues describes how chemicals from the vine stop the gut breaking DMT down, so it works when swallowed. Ibogaine hits many targets at once, as a 2024 Nature Medicine paper by Cherian and colleagues sets out. How psilocybin, DMT and ibogaine work and where each could fit in treatment is reviewed in a 2022 paper Dr Vorobyeva co-wrote in Frontiers in Pharmacology.
The door matters for the experience itself. A 2024 meta-analysis by Dahan and colleagues in npj Mental Health Research found that how strongly people felt the experience explained about 5 to 10 percent of the variation in ketamine’s results and 24 percent of psilocybin’s. The intensity of the experience appears to weigh more on psilocybin’s result than on ketamine’s, though these are correlations, not proof of cause.
What they share: a window of plasticity, not a cure on its own
Each of the four has some evidence of a period in which the brain changes more easily than usual, though the evidence is not equally strong. Dr Vorobyeva puts it plainly: “All of them work through neuroplasticity.” That period is a window, and what gets built in it depends on the person and the people working with them.
For ketamine the evidence is the synapse growth described above, in rats. For psilocybin, a 2021 study in mice by Shao and colleagues in Neuron found that a single dose raised the number and size of dendritic spines, the small points where nerve cells connect, by about 10% within 24 hours; these too are animal data. For ayahuasca, a 2024 review by Egger and colleagues in Cellular and Molecular Life Sciences suggests that DMT together with the vine’s chemicals may promote neuroplasticity. For ibogaine, Cherian and colleagues note that it makes cells produce more BDNF and GDNF, two proteins that help nerve cells grow and connect.
Dr Vorobyeva is direct about what this means for ketamine: “Ketamine is not a magic drug that treats depression by itself.” A session opens the window. What a person does with it is the subject of preparation before it and integration after it.
Why ketamine is medicine now and ayahuasca may never be
Ketamine is one molecule, so a dose can be measured, tested and repeated. Ayahuasca is a brew that changes from batch to batch, which makes the trials regulators ask for hard to run.
One molecule you can dose, or a brew you cannot
When Callaway analysed 29 ayahuasca brews from four sources (Journal of Psychoactive Drugs, 2005), he found “considerable variations in alkaloid profiles”, and in some no DMT was detected at all. DMT is “integral (but not exclusive)” to the brew, Egger and colleagues write, so clinical research turns to synthetic DMT. Dr Vorobyeva draws the line here:
“Ayahuasca is an amazing tool, but I’m not sure it will ever be available in a clinical setting, simply because of dosing. It is not one molecule. You can’t measure the dose, so you can’t design the clinical trial that shows it is safe and gets it through regulation. So I’d separate two groups. Some psychedelics are great tools that may help many people, but they will stay in a grey area, unregulated, because there is no way to take them [to the FDA]. And there is a clinical group, ketamine and MDMA, which will be regulated and used in clinical settings.”
Ibogaine meets the same wall: a 2026 review by Esperança and colleagues names “limited phytochemical validation and standardization of available formulations, and unresolved concerns regarding cardiac safety”.
Where psilocybin and MDMA sit on the clinical route
Psilocybin takes the clinical route as one measured molecule: the 2022 NEJM trial by Goodwin and colleagues used a synthetic formulation, not mushrooms. MDMA’s road is longer: the FDA named MDMA therapy for PTSD a breakthrough in 2017, then rejected the first application in 2024 and asked for another phase 3 trial, the large trial a licence needs (Wolfgang, 2025). The FDA’s final guidance of July 2026 says designing studies of psychedelic drugs “presents a number of unique challenges”.
Four substances, four numbers
- 64% against 28%. Response 24 hours after one ketamine infusion, against an active placebo, in a 2013 trial of 73 people
- 29 brews. Ayahuasca samples analysed in 2005, with alkaloid content varying within and between sources
- 5 to 10% against 24%. How much of the variation in results the strength of the experience explains, ketamine against psilocybin, in a 2024 meta-analysis
- 12 to 16 hours. Heart monitoring after an ibogaine dose in a 2024 study of 30 veterans
What the evidence for depression shows: speed and durability
Ketamine and psilocybin both have randomised trials in depression that had resisted other treatment. Ketamine’s effect is measured a day after a session, psilocybin’s weeks after a single dose. No trial has yet compared the two directly.
In the trial by Murrough and colleagues (American Journal of Psychiatry, 2013), 73 people with treatment-resistant depression received one infusion of ketamine or of midazolam, a sedative used as an active placebo. At 24 hours, 64% responded on ketamine against 28% on midazolam. The authors asked for more data on how long the response lasts.
In the phase 2 trial, a mid-sized trial that tests dose and effect before the large one, by Goodwin and colleagues (NEJM, 2022), 233 people with treatment-resistant depression received one dose of psilocybin with psychological support. A 25 mg dose lowered depression scores by about 12 points at three weeks, against about 5 on a 1 mg control; 10 mg did not differ significantly from control. The 25 mg dose came with side effects, and the authors called for larger, longer trials and comparison with existing treatment.
These are different trials with different measures, timepoints and people, so what they show is a difference in speed, measured in different ways. For ayahuasca and ibogaine in depression, the studies so far are early-phase or uncontrolled, as a 2026 review of registered ayahuasca trials by Stojanović and colleagues and the Cherian study show.
A psychiatrist and an anaesthetist decide whether the programme suits you, given your depression and what you have already tried, at a medical assessment that follows a 15-minute call about the programme.
How the risks differ
Ketamine’s risks mostly come during and soon after the session. Ibogaine’s main risk is to the heart, ayahuasca’s is how it combines with other medicines, and psilocybin brings its own side effects and a long day under supervision.
- Ketamine. A 2025 meta-analysis of 47 studies by Guo and colleagues in Frontiers in Pharmacology found dizziness, dissociation, nausea and blurred vision common, with a brief rise in blood pressure and sleepiness after the dose. Serious side effects were not significantly more common than on placebo. Ketamine can also be misused, and frequent heavy use outside medical care is linked to bladder damage. It is not suitable for everyone, for example people with uncontrolled high blood pressure or a history of psychosis, which is why a medical assessment comes first.
- Psilocybin. In the Goodwin trial, headache, nausea and dizziness were the most common side effects, and suicidal thoughts, suicidal behaviour or self-injury were reported in all dose groups, so trials screen and follow people closely. In a 2026 trial of psilocybin for PTSD by Armstrong and colleagues, the session ran about eight hours with both facilitators present throughout.
- Ayahuasca. Computer modelling by Ribeiro and colleagues (2026) suggests that fluoxetine and paroxetine, two common prescriptions for depression, raise the levels of its active alkaloids in the blood. The vine’s alkaloids block an enzyme (MAO-A) that breaks down serotonin, so combining ayahuasca with antidepressants such as SSRIs carries a risk of serotonin toxicity, which can be dangerous. Anyone taking antidepressants should not take ayahuasca without medical advice.
- Ibogaine. It “has been associated with instances of fatal cardiac arrhythmia”, Cherian and colleagues write; their protocol added magnesium and monitored the heart for 12 to 16 hours.
Dr Vorobyeva’s view covers all four:
“It is not for everyone. We need to be aware of contraindications and prescribe only when we know it will be safe for the person and will help. It is a great tool, and we should use it when there is a benefit for that particular person.”
With ketamine at Hive, a doctor and a nurse stay with you through each session. The two doctors who lead the medical assessment decide whether the programme suits you from your health, your medication and what you have tried. Ketamine’s side effects, and what is normal after a session, have a page of their own.
What you can legally get, in brief
Ketamine is licensed as an anaesthetic and prescribed for depression off-label, which is legal in the US, the UK, the EU, Canada and Australia when a doctor takes responsibility for it; the rules in each country are on their own page. Esketamine, a form of ketamine given as a nasal spray, is licensed for treatment-resistant depression in the US, the UK and the EU. Psilocybin can be taken legally at licensed service centres in Oregon and Colorado, and authorised psychiatrists in Australia can prescribe it for treatment-resistant depression; how psilocybin retreats compare with ketamine on supervision and safety is set out separately. Ayahuasca and ibogaine have not been through the trials a medicine licence needs.
Whichever you choose, plan the integration
Whichever substance you choose, the session is one part of the work. Dr Vorobyeva on ketamine given by itself: “An infusion on its own gives a short-term antidepressant effect. Nothing gets built on top of it.” Integration is the work of turning what came up in a session into changes in daily life, and what that work involves after a psychedelic session has its own page.
She is as clear that plans differ from person to person:
“Physical and mental health are personal. If something works for someone, it doesn’t mean it will work for you.”
That is the case for choosing by evidence and access over the intensity of the experience, and for planning integration before the first session. At Hive, the seven-day retreat on Gozo holds three or four sessions, depending on the person, inside a seven-week programme with preparation before and online integration after; there is also an outpatient course of six infusions over three weeks at our partner clinic in Malta: how the programme runs. The first step is a short call with the team, and the medical assessment with the doctors comes after it.
Find out whether the programme fits you
Tell us what you are dealing with and what you have already tried. Whether it suits you is decided by two doctors at the medical assessment, before you pay for the programme.
No payment and no booking at this step.
Common questions
Is ketamine or psilocybin better for treatment-resistant depression?
No trial has compared them directly. Ketamine has a randomised trial with 64% response at 24 hours against 28% on an active placebo; psilocybin has a phase 2 trial in which 25 mg lowered depression scores more than a control dose at three weeks. At assessment the doctors look at what you have already tried; meet the doctors who run it.
Can you do ketamine and psilocybin together?
Their combination has not been studied in human trials, so no safe schedule for combining them has been worked out. Each acts on a different system in the brain. Do not combine them on your own. If you have used psilocybin or plan to, tell the doctors at your assessment; ask the team before you book.
Ketamine vs microdosing
Microdosing means taking small, regular doses of a classic psychedelic such as psilocybin or LSD, below the dose that changes perception. In a 2021 study of 191 people in eLife, the largest placebo-controlled study of psychedelics at the time, both groups improved and the difference between them was not significant; participants set up their own placebo without clinical supervision. Ketamine for depression has been tested against an active placebo under medical care. Ask the team how a ketamine course is supervised.
Is ketamine derived from mushrooms?
No. Ketamine is a synthetic drug, made in a laboratory and licensed as an anaesthetic. Psilocybin is the compound in so-called magic mushrooms, and the trials use a synthetic version: a 2026 review by Enriquez-Geppert and colleagues ranks purified psilocybin as the most reliable dose and whole mushrooms as the least. See how a ketamine week on Gozo runs.
Ketamine acts on the brain’s glutamate system, psilocybin and ayahuasca act on serotonin receptors, and ibogaine acts on many targets; in animal studies ketamine and psilocybin open a short window when the brain forms new connections more easily, and ayahuasca and ibogaine may do the same. Ketamine is one synthetic molecule, licensed as an anaesthetic and prescribed off-label for depression, and in a 2013 trial 64% responded at 24 hours against 28% on an active placebo. Psilocybin is in trials as a synthetic formulation, and no trial has compared it with ketamine directly. Ayahuasca’s alkaloid content varied across 29 brews in one analysis, and ibogaine carries a risk of fatal heart rhythm problems. Whether a dose can be measured and tested is what turns a substance into a prescribed medicine.